Guidelines Calls

Call open · Closes 15 October 2026

Develop a new European guideline.

The European Dermatology Forum invites clinicians and researchers across Europe to lead the next EuroGuiDerm clinical guidelines. This call covers two priority topics where European practice needs a single, evidence-graded reference. You do not need to be an EDF member to apply.

Choose a topic
Read the proposal brief

Funded · published in JEADV

STEP 1 — SELECT YOUR TOPIC

Two priority topics — or your own

Choose the guideline you intend to lead, or propose a subject of your own. The brief below updates to show the clinical need, proposed scope and the expertise your group should bring.

A major update for the JAK-inhibitor era.

Guideline update · up to 15 months

European guidance on vitiligo was last harmonised in 2013. Topical JAK inhibition (ruxolitinib cream, EMA-approved for non-segmental vitiligo in 2023), advances in phototherapy and a growing systemic pipeline have moved well past that consensus. Clinicians need an updated, evidence-graded algorithm for assessment, treatment sequencing and maintenance.

Proposed scope

  • Classification (segmental vs non-segmental) and disease activity assessment

  • Validated outcomes — VASI, repigmentation thresholds, patient-reported measures

  • Topical therapy, including JAK and calcineurin inhibitors

  • Phototherapy (NB-UVB) and combination regimens

  • Systemic and emerging therapies

  • Maintenance, relapse prevention and special sites

  • Paediatric care, psychological support and shared decision-making

Target users: Dermatologists, paediatric dermatologists, GPs with a dermatology interest, patient representatives.

Expertise sought: Pigmentary disorders, phototherapy, paediatric dermatology, methodology, patient advocacy.

Europe's first EuroGuiDerm standard for autoimmune hair loss.

New guideline · up to 24 months

Alopecia areata has no harmonised European guideline, yet the field has changed fundamentally. Baricitinib (2022) and ritlecitinib (2023) are now EMA-approved for severe disease, including adolescents. European dermatology needs one evidence-graded reference covering severity staging, treatment selection, monitoring and the management of relapse.

Proposed scope

  • Severity assessment and staging (SALT and beyond)

  • Topical, intralesional and systemic corticosteroid use

  • Contact immunotherapy for extensive disease

  • Oral JAK inhibitors — selection, monitoring and stopping rules

  • Paediatric and adolescent treatment pathways

  • Relapse and long-term management

  • Eyebrow, eyelash and nail involvement; psychosocial impact

Last official guidance
Target users: Dermatologists, trichology specialists, paediatric dermatologists, patient representatives.
Expertise sought: Hair disorders, autoimmunity, paediatric dermatology, pharmacovigilance, methodology, patient advocacy.

Propose a subject of your own.

New guideline or update · scope you define

These two topics are this cycle's priorities, but the EDF welcomes proposals on any area of dermatology and venereology where European practice would benefit from a single, evidence-graded reference. You define the subject, the clinical need and the scope; the EDF Guideline Commission assesses it on clinical relevance, methodological rigour, collaboration and feasibility.

Proposed scope

  • Define the population and the clinical questions (PICO / PIRT)

  • Set the outcomes that matter, with adverse events included

  • State what existing guidance exists and what your project adds

  • Choose the methodology — systematic review, Delphi or adaptation

  • Propose a multidisciplinary group across at least five countries

  • Include patient representation and a dissemination plan

Last official guidance

  • No preset reference for an open subject — cite the current evidence and any existing national or international guidance in your proposal.

Target users: Defined by your proposal.
Expertise sought: Matched to your topic; methodology and patient advocacy in every group.

The call in brief

At a glance

Funding
€40,000
Up to €40,000 for a new guideline, €25,000 for an update. Paid in two instalments — half on selection, half on completion.
Timeline
Up to 24 mo
New guidelines up to 24 months; updates up to 15 months.
Output
JEADV
Published in JEADV. Reviewed every 3–5 years.
Submission
15 Oct
Deadline 15 October 2026, 23:59 CET. No EDF membership required; filed by the lead applicant through the application form.

Who can apply

Eligibility

  • Open to members of EDF, EADV or affiliated national societies, guideline groups, and individuals or institutions with relevant expertise. Membership is not required.

  • One proposal as Convenor per call. Convenors may not be voting members of the EDF Guideline Commission.

  • The topic meets a clear clinical need. No commercial sponsorship.

Build your panel

Guideline group

Propose a complete, multidisciplinary group led by you as Convenor (or joint convenors).

1 Convenor / joint

1 Methodologist

1 Fellow

2 Patient representatives

2 Young investigators

1 Health professional

≤5 Open-call members

↳ Experts from at least 5 countries
↳ Up to 25 members in total
↳ No member on more than 3 active guideline groups

Conflicts of interest. All members declare interests from the last five years on submission and keep them updated throughout; declarations are published with the guideline. Members with an interest involving a drug manufacturer are excluded from voting on recommendations concerning that company's drugs.

What to submit

What your proposal covers

One document, in English. Methods and your team matter most. Projects may use systematic review, a Delphi process or adaptation, depending on type.

  • Proposal, abstract & lay summary
    The guideline you propose and its objectives, in full and in plain language.

  • Clinical need
    What is already known, what this project adds, and its effect on practice.

  • Methodology
    Your review approach, evidence grading and consensus process.

  • Group & declarations
    Composition and countries, with a declaration of interest for every member.

  • Timeline & budget
    A     timeline with milestones and a short, justified budget.

  • Dissemination plan
    How the guideline will be published, translated and communicated.

How EuroGuiDerm works

Methodology you commit to

Projects follow the EDF methodology for European dermatology guidelines. Proposals must show how these standards will be applied.

M1

Structured questions

PICO for intervention questions, PIRT for diagnostic. Outcomes ranked 1–9 by importance (GRADE).

M2

Systematic review

Per the Cochrane Handbook: search strategy, risk of bias and evidence tables. A librarian or methodologist is strongly advised.

M3

Consensus & voting

Up to 5 overarching principles and 10–15 recommendations. Consensus is reported as percentage agreement — strong consensus >95%, consensus >75–95% — with >50% the minimum to include a recommendation.

M4

Managed conflicts

All members declare interests from the last five years. Members with an interest involving a drug manufacturer do not vote on recommendations about that company's drugs.

Before submission, the draft guideline is reviewed by EDF members who are specialists in the relevant field.

How proposals are judged

Evaluation criteria

01

Clinical relevance

Meets a real gap in European practice with clear benefit to patients.

02

Methodological rigour

A credible review, GRADE grading and a sound consensus plan.

03

Collaboration

A multidisciplinary group across countries, with patients involved.

04

Feasibility

A realistic timeline, clear roles and a sensible budget.

After you submit

How proposals are reviewed

Three stages, ending in a decision by the EDF Guideline Commission.

Stage 1

Pre-eligibility

A quick check that the topic is relevant and within scope.

Stage 2

Eligibility

Review for administrative and methodological completeness.

Stage 3

Commission decision

Approval, a request to revise, or rejection by the EDF Guideline Commission.

From idea to submission

How to apply

  • Assemble your group
    Line up your Convenor, methodologist and patient representatives. No EDF membership needed.

  • Draft your proposal
    Cover the six parts above, with most attention on methods and your team.

  • Collect declarations
    Each proposed member submits a conflict-of-interest declaration.

  • Submit the form
    Complete the online application before the deadline.

Ready to lead

Start your

guideline proposal

Complete the online application form — no EDF membership

required. The form produces a structured record of your

proposal.

Start your application →

Submission deadline: 15 October 2026, 23:59 CET · Proposals to guidelines@euroderm.org

This website uses cookies!

We use cookies to tailor our content to your needs and continuously improve our website. You can decide which cookies you want to allow. Detailed information about the cookies we use can be found in our Privacy Policy and Cookie Settings. You can withdraw your consent at any time.